Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
MTEM | US
0
0%
Healthcare
Biotechnology
30/06/2024
21/10/2024
0.75
0.74
0.83
0.70
Molecular Templates Inc. a clinical stage biopharmaceutical company focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company primarily develops therapies through its proprietary biologic engineered toxin body (ETB) drug platform. The company is developing MT- 8421 an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169 which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates Inc. was founded in 2001 and is headquartered in Austin Texas.
View LessValue Stock (Price to Book < 3)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
High Debt to Equity (> 0.75)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
1004.8%1 month
732.7%3 months
412.1%6 months
299.8%-
-
0.86
1.55
0.41
0.15
0.21
-
-13.87M
4.94M
4.94M
-
-1.45K
-97.20
-91.70
-929.14
3.02
3.07
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.19
Range1M
1.19
Range3M
1.29
Rel. volume
0.11
Price X volume
1.09M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
PALISADE BIO INC | PALI | Biotechnology | 3.91 | 5.41M | 0.51% | n/a | 5.06% |
ERNA | ERNA | Biotechnology | 0.9899 | 5.36M | -2.95% | n/a | -577.12% |
XORTX Therapeutics Inc. Common Stock | XRTX | Biotechnology | 1.71 | 5.15M | -9.04% | n/a | 3.09% |
BIONOMICS LIMITED/FI | BNOX | Biotechnology | 0.2955 | 5.12M | -1.53% | n/a | 0.59% |
180 Life Sciences Corp | ATNF | Biotechnology | 4.97 | 5.10M | -1.19% | n/a | -105.81% |
QLGN | QLGN | Biotechnology | 0.1825 | 4.93M | 9.15% | n/a | -39.04% |
Enveric Biosciences Inc | ENVB | Biotechnology | 0.538 | 4.80M | 20.33% | n/a | 0.00% |
CNS PHARMACEUTICALS INC | CNSP | Biotechnology | 0.146 | 4.69M | 19.67% | n/a | -2.87% |
Azitra Inc | AZTR | Biotechnology | 0.61 | 4.65M | 0.00% | 0.01 | 41.86% |
ADTX | ADTX | Biotechnology | 1.09 | 4.60M | 3.81% | n/a | 122.46% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 0.15 | 0.53 | Cheaper |
Ent. to Revenue | 0.21 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 0.86 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 412.15 | 72.80 | Riskier |
Debt to Equity | 1.55 | -1.23 | Expensive |
Debt to Assets | 0.41 | 0.25 | Expensive |
Market Cap | 4.94M | 3.66B | Emerging |